By Julia Karow

A year after receiving the PacBio RS single-molecule sequencer in their labs, early-access customers from two research institutions have taken their instruments through their paces and are starting to analyze "real" samples.

As users at the Wellcome Trust Sanger Institute and the National Cancer Institute become more familiar with the type of data the instrument produces, they expect to apply their machines more routinely this year for projects that can benefit from long reads.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.